Fischer Medical Ventures Ltd (FISCHER) AI Stock Analysis

0 Followers

Fischer Medical Ventures Ltd

(NSE:FISCHER)

Select Model

Rating:55Neutral

Price Target:INR 28.00▲(11.29% Upside)

Action:reiterated

Date:10/27/26

The overall score is heavily weighed down by severe cash burn and a strongly bearish technical trend, despite exceptional revenue growth and a well-capitalized balance sheet. While the equity position is robust, the premium P/E valuation and deteriorating cash conversion present significant near-term risks that limit the stock's broader appeal.

Positive Factors

Revenue GrowthThe sharp FY2026 revenue increase demonstrates a substantial expansion in reported business scale. If the higher level is sustained, it can improve operating leverage, support investment in the company’s medical focus, and provide a stronger base for future earnings generation.

Negative Factors

Persistent Cash BurnDeeply negative operating and free cash flow despite reported accounting profitability is a major durability concern. Continued cash burn can increase reliance on external funding, reduce financial flexibility, and make the recent earnings improvement less valuable unless cash conversion improves materially.

Fischer Medical Ventures Ltd (FISCHER) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 16.71B
Dividend Yield: 0.20%
Average Volume (3M): 80.41K
Price to Earnings (P/E): 54.9
Beta (1Y): 0.37
Revenue Growth: 195.95%
EPS Growth: 1526.86%
Country: India
Employees: 40
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Fischer Medical Ventures Ltd Business Overview & Revenue Model

Company Description

Fischer Medical Ventures Limited, established in 1993 and headquartered in Chennai, India, is a global provider of medical equipment. The company's operations encompass the manufacturing, distribution, leasing, and maintenance of a wide array of medi...

Fischer Medical Ventures Ltd Financial Statement Overview

Summary

Impressive top-line expansion and a well-capitalized balance sheet are heavily offset by severe and deteriorating cash burn, resulting in deeply negative operating and free cash flows.

Income Statement

92Very Positive

Balance Sheet

85Very Positive

Cash Flow

25Negative

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2022
Income Statement
Total Revenue	3.67B	3.09B	1.11B	209.81M	0	1.79M
Gross Profit	1.06B	949.12M	191.09M	45.27M	0	1.79M
EBITDA	525.56M	430.83M	42.41M	23.61M	-1.89M	152.00K
Net Income	298.13M	312.41M	12.08M	18.38M	-2.33M	-365.00K
Balance Sheet
Total Assets	0	6.72B	4.57B	863.22M	1.90M	3.54M
Cash, Cash Equivalents and Short-Term Investments	250.46M	250.46M	2.51B	379.46M	156.00K	358.00K
Total Debt	0	1.07B	853.72M	16.77M	3.89M	11.43M
Total Liabilities	-3.87B	2.86B	1.20B	52.07M	4.20M	6.20M
Stockholders Equity	3.87B	3.85B	3.38B	811.14M	-2.29M	-2.66M
Cash Flow
Free Cash Flow	-778.10M	-1.29B	-927.25M	-78.37M	-1.77M	-1.46M
Operating Cash Flow	-694.93M	-1.01B	-867.38M	-73.52M	-1.77M	-1.46M
Investing Cash Flow	-985.52M	-86.20M	-1.25B	-313.86M	0	1,000
Financing Cash Flow	-404.42M	167.56M	3.15B	370.57M	1.48M	1.66M

Fischer Medical Ventures Ltd Technical Analysis

Technical Analysis SentimentNegative

Last Price25.16

Price Trends

50DMA30.98Negative

100DMA34.44Negative

200DMA35.99Negative

Market Momentum

MACD-1.86Negative

RSI37.42Neutral

STOCH29.72Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FISCHER, the sentiment is Negative. The current price of 25.16 is below the 20-day moving average (MA) of 26.24, below the 50-day MA of 30.98, and below the 200-day MA of 35.99, indicating a bearish trend. The MACD of -1.86 indicates Negative momentum. The RSI at 37.42 is Neutral, neither overbought nor oversold. The STOCH value of 29.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FISCHER.

Fischer Medical Ventures Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:FISCHER against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:KRSNAA	70Outperform	INR 16.01B	16.57	―	0.40%	15.90%	15.67%
IN:SAKAR	66Neutral	INR 22.58B	55.82	―	―	47.99%	117.99%
IN:NURECA	58Neutral	INR 2.93B	64.20	―	―	33.66%	17.10%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:FISCHER	55Neutral	INR 16.36B	54.88	―	0.20%	195.95%	1526.86%
IN:NGLFINE	54Neutral	INR 18.11B	31.69	―	0.06%	40.45%	174.03%
IN:TARSONS	54Neutral	INR 16.86B	155.55	―	―	10.63%	-59.63%

* General Sector Average

Performance Comparison

IN:FISCHER and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:FISCHER	Fischer Medical Ventures Ltd	25.16	-33.55	-57.15%
IN:KRSNAA	Krsnaa Diagnostics Limited	502.10	-299.88	-37.39%
IN:NGLFINE	NGL Fine-Chem Ltd.	2913.70	1524.53	109.74%
IN:NURECA	Nureca Ltd.	301.15	26.65	9.71%
IN:SAKAR	Sakar Healthcare Ltd	1075.70	680.75	172.36%
IN:TARSONS	Tarsons Products Limited	324.65	84.95	35.44%

Fischer Medical Ventures Ltd Corporate Events

Fischer Medical Ventures to Email FY26 Annual Report and Hold Virtual AGM

Sep 5, 2026

Fischer Medical Ventures Ltd has notified stock exchanges that its Annual Report for the financial year 2025–26 will be dispatched to shareholders electronically, in line with regulatory allowances for digital communication. The company also announce...

Fischer Medical Ventures Plans One-to-One Virtual Meet With Institutional Investors

Sep 4, 2026

Fischer Medical Ventures Ltd has announced that it will host a one-to-one virtual meeting with institutional investors on Monday, 7 September 2026 at 12:30 p.m. IST. The session will focus on the company’s business and general information already ava...

Fischer Subsidiary TMIV Imaging Debuts AI-Driven CLARION CT System in India

Aug 28, 2026

Time Medical International Ventures (India) Private Ltd., the wholly owned subsidiary of Fischer Medical Ventures Limited, has launched its next-generation CLARION 64/128-slice AI-driven CT system in India, unveiled at the India Health Expo 2026. The...

Fischer Medical Ventures Opens SEBI-Compliant Window for Physical Share Transfer Re-Lodgement

Aug 11, 2026

Fischer Medical Ventures Ltd has announced that it has published newspaper advertisements in Financial Express and Vishalandra to inform shareholders about a SEBI-mandated special window for re-lodgement of transfer requests for physical shares. The...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 27, 2026

Fischer Medical Ventures Ltd AI Stock Analysis